Abstract Search

10.6. Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories

BC Kwon , V Anand , P Achenbach , JL Dunne , W Hagopian , J Hu , E Koski , AE Lernmark , M Lundgren , K Ng , J Toppari , R Veijola , BI Frohnert

T1DI Study Group. Nat Commun. 2022 Mar 21;13(1):1514. https://pubmed.ncbi.nlm.nih.gov/35314671/Brief Summary: This study of 5 birth cohorts of individuals at high risk for type 1 diabetes (T1D) used machine learning methods to explore trajectories from autoantibodies appearance to T1D progression. They identified 11 distinct latent health states and individuals progressed according to one o...

0 shares

ey0015.15-6 | New treatments | ESPEYB15

15.6 Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

HS Taylor , LC Giudice , BA Lessey , MS Abrao , J Kotarski , DF Archer , MP Diamond , E Surrey , NP Johnson , NB Watts , JC Gallagher , JA Simon , BR Carr , WP Dmowski , N Leyland , JP Rowan , WR Duan , J Ng , B Schwefel , JW Thomas , RI Jain , K Chwalisz

To read the full abstract: N Engl J Med 2017;377:28-40We highlight this paper for 3 reasons. First, remarkably there are few robust data on effective treatment options for endometriosis. Subcutaneous GnRH antagonists are sometimes used off-label, but with very limited evidence. Secondly, the clear findings here confirm the pathogenesis of endometriosis as being driven by an over-act...

0 shares

ESPE Yearbook of Paediatric Endocrinology

10.6. Progression of type 1 diabetes from latency to symptomatic disease is predicted by distinct autoimmune trajectories

15.6 Treatment of Endometriosis-Associated Pain with Elagolix, an Oral GnRH Antagonist

BiosciAbstracts